In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3317-3322

  Barchiesi, Francesco ^a   Spreghini, Elisabetta ^a   Maracci, Monia ^a   Fothergill, Annette W ^b   Baldassarri, Isabella ^a   Rinaldi, Michael G ^b,c   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA GLABRATA; CONTROLLED STUDY; DIFFUSION; DILUTION; DRUG ACTIVITY; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; DRUG COMBINATIONS; DRUG SYNERGISM; FLUCYTOSINE; KINETICS; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; PYRIMIDINES; TRIAZOLES;

EID: 4344607756     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3317-3322.2004     Document Type: Article

References (39)

1. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.
2. Bachmann, S. P., G. Ramage, K. VandeWalle, T. F. Patterson, B. L. Wickes, and J. L. Lopez-Ribot. 2003. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob. Agents Chemother. 47:3657-3659.
3. Barchiesi, F., A. M. Schimizzi, L. K. Najvar, R. Bocanegra, F. Caselli, S. Di Cesare, D. Giannini, L. F. Di Francesco, A. Giacometti, F. Carle, G. Scalise, and J. R. Graybill. 2001. Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 45:1355-1359.
4. Barchiesi, F., A. M. Schimizzi, F. Caselli, A. Novelli, S. Fallani, D. Giannini, D. Arzeni, S. Di Cesare, L. F. Di Francesco, M. Fortuna, A. Giacometti, F. Carle, T. Mazzei, and G. Scalise. 2000. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:2435-2441.
5. Barchiesi, F., D. Gallo, F. Caselli, L. F. Di Francesco, D. Arzeni, A. Giacometti, and G. Scalise. 1999. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J. Antimicrob. Chemother. 44:65-70.
6. Barchiesi, F., L. F. Di Francesco, P. Compagnucci, D. Arzeni, A. Giacometti, and G. Scalise. 1998. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41:59-65.
7. Barchiesi, F., L. F. Di Francesco, and G. Scalise. 1997. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41:1812-1814.
8. Como, J. A., and W. E. Dismukes. 1994. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330:263-272.
9. Edmond, M. B., S. E. Wallace, D. K. McClish, M. A. Pfaller, R. N. Jones, and R. P. Wenzel. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:239-244.
10. Eliopoulos, G. M., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
11. Gosbell, I. B., V. Toumasatos, J. Yong, R. S. Kuo, D. H. Ellis, and R. C. Perrie. 2003. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 46:233-236.
12. Grayhill, J. R., R. Bocanegra, L. K. Najvar, S. Hernandez, and R. A. Larsen. 2003. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob. Agents Chemother. 47:2373-2375.
13. Howden, B. P., M. A. Slavin, A P. Schwarer, and A. M. Mijch. 2003. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis. 22:111-113.
14. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
15. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.
16. Lewis, R. E., B. C. Lund, M. E. Klepser, E. J. Ernst, and M. A. Pfaller. 1998. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. 42:1382-1386.
17. Louie, A., P. Banerjee, G. L. Drusano, M. Shayegani, and M. H. Miller. 1999. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob. Agents Chemother. 43:2841-2847.
18. Luque, J. C., K. V. Clemens, and D. A. Stevens. 2003. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob. Agents Chemother. 47:1452-1455.
19. Meletiadis, J., J. W. Mouton, J. F. Meis, and P. E. Verweij. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47:106-117.
20. Meletiadis, J., J. W. Mouton, J. L. Rodriguez-Tudela, J. F. G. M. Meis, and P. E. Verweij. 2000. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 44:470-472.
21. Mosquera, J., A. Sharp, C. B. Moore, P. A. Warn, and D. W. Denning. 2002. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J. Antimicrob. Chemother. 50:189-194.
22. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeast, 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
23. Nguyen, M. H., L. K. Najvar, C. Y. Yu, and J. R. Graybill. 1997. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41:1120-1123.
24. Odds, F. C. 2003. Synergistic, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
25. Onyewu, C., J. R. Blankenship, M. Del Poeta, and J. Heitman. 2003. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 47:956-964.
26. Perea, S., G. Gonzalez, A. W. Fothergill, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46:3039-3041.
27. Perea, S., G. Gonzalez, A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. 2002. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J. Clin. Microbiol. 40:1831-1833.
28. Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
29. Pfaller, M. A., S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2003. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J. Clin. Microbiol. 41:2176-2179.
30. Redding, S. W., W. R. Kirkpatrick, S. Saville, B. J. Coco, W. White, A. Fothergill, M. Rinaldi, T. Eng, T. F. Patterson, and J. Lopez-Ribot. 2003. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol. 41:619-622.
31. Rex, J. H., P. G. Pappas, A. W. Karchmer, J. Sobel, J. E. Edwards, S. Hadley, C. Brass, J. A. Vazquez, S. W. Chapman, H. W. Horowitz, M. Zervos, D. McKinsey, J. Lee, T. Babinchak, R. W. Bradsher, J. D. Cleary, D. M. Cohen, L. Danziger, M. Goldman, J. Goodman, E. Hilton, N. E. Hyslop, D. H. Kett, J. Lutz, R. H. Rubin, W. M. Scheld, M. Schuster, B. Simmons, D. K. Stein, R. G. Washburn, L. Mautner, T. C. Chu, H. Panzer, R. B. Rosenstein, J. Booth, and National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36:1221-1228.
32. Sanati, H., C. F. Ramos, A. S. Bayer, and M. A. Ghannoum. 1997. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob. Agents Chemother. 41:1345-1348.
33. Snydman, D. R. 2003. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 123:500S-503S.
34. Sugar, A. M., C. A. Hitchcock, P. F. Troke, and M. Picard. 1995. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39:598-601.
35. Te Dorsthorst, D. T., P. E. Verweij, J. Meletiadis, M. Bergervoet, N. C. Punt, J. F. Meis, and J. W. Mouton. 2002. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob. Agents Chemother. 46:2982-2989.
36. Te Dorsthorst, D. T. A., P. E. Verweij, J. F. G. M. Meis, N. C. Punt, and J. W. Mouton. 2002. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob. Agents Chemother. 46:702-707.
37. Viscoli, C., C. Girmenia, A. Marinus, L. Collette, P. Martino, B. Vandercam, C. Doyen, B. Lebeau, D. Spence, V. Krcmery, B. De Pauw, and F. Meunier. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1079.
38. Weig, M., and F. M. C. Müller. 2001. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 45:966-968.
39. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.